“Quintiles is the clear market leader in the Asia Pacific CRO landscape,” said Rhenu Bhuller, partner, healthcare, Frost & Sullivan. “Asia Pacific is a strong focus area for multinational CROs and we evaluated the top five on two key factors—‘visionary innovation and performance’ and ‘customer impact.’ Quintiles scored highly in all criteria, and particularly so in ‘pioneering best practices’ and ‘addressing biopharma’s unmet needs.’
“For example, Quintiles launched a dedicated medical devices unit in Asia Pacific in 2015 that leverages the expertise of Novella Clinical, a Quintiles company. It also introduced a custom-tailored set of solutions for Asia Pacific emerging biopharma. Both of these are fast-growing market sectors and ones in which government and industry are trying to build capabilities. Quintiles is well-positioned to support this growth.”
Frost & Sullivan, a business research and consulting firm, also cited Quintiles’ continued expansion of services in Asia Pacific, particularly in Greater China, Japan and South Korea, and its use of innovative technologies to improve efficiency and quality.
Quintiles opened its first Asia Pacific office (Tokyo) in 1993 and this year is celebrating the 20th anniversary of Quintiles Singapore, its Asia Pacific regional headquarters. With a database of more than 17,000 investigator sites or hospitals across Asia Pacific, Quintiles has conducted more than 1,100 studies covering a wide range of therapeutic areas—including cardiovascular disease, oncology, neurology and infectious diseases—involving almost 250,000 patients since 2000.
Over the last 12 months Quintiles has won the Vaccine Industry Excellence Best CRO Award, received SCRIP Awards Best CRO honors and been named to the InformationWeek Elite 100.